Nebivolol suppresses glioblastoma progression via dual modulation of mitochondrial metabolism and AKT/mTOR/4EBP1 signaling axis
PLOS Genetics · 24.04.2026 · 22 (4) · e1012120
DOI: 10.1371/journal.pgen.1012120 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Genetics, online erschienen am 24.04.2026. Verfasst von Lingni Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Glioblastoma, Nebivolol, Mitochondria, Adaptor Proteins, Signal Transducing. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Jiangsu Province, Construction Project of High Level Hospital of Jiangsu Province.
Abstract (Originalsprache)
Emerging evidence reveals the pivotal involvement of mitochondrial metabolic dysregulation in glioblastoma (GBM) pathogenesis, considering mitochondrial metabolism as a potential therapeutic target. Nebivolol, a third-generation β-adrenergic receptor antagonist clinically employed in cardiovascular diseases, has recently exhibited notable anti-neoplastic properties. Nevertheless, its therapeutic efficacy and mechanistic underpinnings in GBM remain largely unexplored. In this investigation, we comprehensively assessed the impact of nebivolol on GBM cellular proliferation and elucidated its molecular mechanisms. Our findings revealed that nebivolol markedly suppressed the proliferation and clonogenic abilities of multiple GBM cell lines, concomitant with cell cycle arrest and apoptotic induction. Mechanistically, nebivolol impaired mitochondrial respiratory chain complex I activity, diminished adenosine triphosphate (ATP) synthesis, and augmented ROS production, collectively precipitating neoplastic cell apoptosis. Furthermore, nebivolol attenuated AKT/mTOR/4EBP1 signaling cascade activation, thereby impeding GBM malignant proliferation. In vivo studies corroborated these observations, demonstrating that nebivolol administration significantly attenuated orthotopic GBM xenograft progression and extended survival in tumor-bearing murine models. This study delineates a novel dual mechanism whereby nebivolol exerts anti-GBM effects through concurrent modulation of mitochondrial bioenergetics and AKT/mTOR/4EBP1 signaling transduction. These results provide robust preclinical evidence supporting nebivolol’s clinical repurposing for GBM therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Insititute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Department of Critical Care Medicine, Yancheng Third People's Hospital, Yancheng, Jiangsu, China.
ORCID-Profile: Xuejiao Liu
Förderung
- Natural Science Foundation of Jiangsu Province
- Construction Project of High Level Hospital of Jiangsu Province
Zitieren
APA
Zhou, L., Che, H., Jiang, H., Yin, L., Jiang, Y., Zhang, Y., Liang, H., Yu, R., Zhang, X., & Liu, X. (2026). Nebivolol suppresses glioblastoma progression via dual modulation of mitochondrial metabolism and AKT/mTOR/4EBP1 signaling axis. PLOS Genetics, 22(4), e1012120. https://doi.org/10.1371/journal.pgen.1012120
Vancouver
Zhou L, Che H, Jiang H, Yin L, Jiang Y, Zhang Y, et al. Nebivolol suppresses glioblastoma progression via dual modulation of mitochondrial metabolism and AKT/mTOR/4EBP1 signaling axis. PLOS Genetics. 2026;22(4):e1012120. doi:10.1371/journal.pgen.1012120
BibTeX
@article{Zhou2026,
author = {Zhou, Lingni and Che, Hongyu and Jiang, Hongyan and Yin, Luxin and Jiang, Yongang and Zhang, Yuhui and Liang, Haoran and Yu, Rutong and Zhang, Xu and Liu, Xuejiao},
title = {Nebivolol suppresses glioblastoma progression via dual modulation of mitochondrial metabolism and AKT/mTOR/4EBP1 signaling axis},
journal = {PLOS Genetics},
year = {2026},
volume = {22},
number = {4},
pages = {e1012120},
doi = {10.1371/journal.pgen.1012120}
}
EUVIMED